Switch to
View more

Hikal Ltd

HIKAL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,974 cr, stock is ranked 562
High RiskStock is 3.03x as volatile as Nifty
315.057.30 (-2.26%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,974 cr, stock is ranked 562
High RiskStock is 3.03x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
24.20
PB RatioPB Ratio
4.16
Dividend YieldDiv. Yield
0.51%
Sector PESector PE
34.97
Sector PBSector PB
4.41
Sector Div YldSctr Div Yld
0.91%

Forecast & RatingsDetailed Forecast 

67%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients and contract research activities. The Company offers pharmaceuticals and agrochemicals.

Investor PresentationView older 

Aug 10, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

20192020202120221.591.511.731.950.100.080.130.16
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Recording of Analysts/Institutional Investor Meet/Con. Call 
Announced OnAug 11, 2022

Hikal Limited has informed the Exchange about Recording of Analysts/Institutional Investor Meet/Con. Call | Download

Hikal Limited has informed the Exchange about Recording of Analysts/Institutional Investor Meet/Con. Call | Download

Investor Presentation 
Announced OnAug 10, 2022

Hikal Limited has informed the Exchange about Investor Presentation on the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2022 | Download

Hikal Limited has informed the Exchange about Investor Presentation on the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2022 | Download

Cash Dividend 
Ex. DateFeb 23, 2022

Interim • Div/Share: ₹ 1.2

See all events